Ditazole activity and its interaction with urokinase on experimental thrombosis.
The effect of ditazole, a new antiaggregant oxazole derivative as well as its possible interaction with urokinase on the formation of electrically induced thrombus, was assayed in rabbits. The activity of ditazole in reducing thrombus weight was comparable to that of aspirin. In the ditazole- or aspirin-treated animals, the microscopical examination of the thrombus showed a reduction in the fibrin component, and well-isolated platelets not undergoing a viscous metamorphosis were present. Urokinase, administered in combination with these antiaggregant drugs, did not induce a further reduction in thrombus weight. However, this additional treatment did induce clearly visible lytic areas and histological modifications as observed with the antiaggregant drugs. These data suggest that the antiplatelet drug ditazole may be an effective antithrombotic agent in man and could facilitate the penetration of urokinase into the thrombus.
D000818:Animals; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use; D002339:Carotid Arteries / Q000473:pathology; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D010450:Endopeptidases / Q000378:metabolism*; D008297:Male; D010080:Oxazoles / Q000494:pharmacology / Q000627:therapeutic use*; D011817:Rabbits; D013927:Thrombosis / Q000188:drug therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism* / Q000494:pharmacology
D010080:Oxazoles; D010450:Endopeptidases; D014568:Urokinase-Type Plasminogen Activator; D001241:Aspirin